SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999, to receive the free SmallCapReview newsletter and be entered to win a Free iPod Touch visit http://www.smallcapreview.com/.
IMAX Corporation (Nasdaq: IMAX) $16.95. Today announced along with AMC Entertainment an expansion of the companies' joint venture agreement to include installation of between 15 and 25 new IMAX theatres in the United States. These theatres, which are part of an amendment to the parties' original 2007 joint venture agreement, are in addition to AMC's current roll-out of 104 IMAX joint venture theatres, 79 of which are in operation and 25 of which are expected to open by the end of 2010 in the United States and Canada.
The companies intend to open the 15 to 25 new IMAX theatres in 2011 in both new markets and some markets where AMC already operates IMAX theatres in North America. Upon completion of the full AMC IMAX theatre roll-out, AMC will operate between 125 and 135 IMAX theatres.
What They Do: IMAX Corporation is one of the world's leading entertainment technology companies, specializing in immersive motion picture technologies.
Oncolytics Biotech (Nasdaq: ONCY) $2.94. Today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
"Obtaining approval to conduct this trial in Belgium will allow us to expand European enrollment in the study and to access leading head and neck specialists," said Dr. Brad Thompson, President and CEO of Oncolytics. "We expect to add Belgian centres over the next quarter as they become available for inclusion in the study."
What They Do: Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Global Industries (Nasdaq: GLBL) $5.22. Today announced that it has been awarded a project from Petroleos Mexicanos (Pemex) for pipeline work in Pemex's Ku-Maloob-Zaap Field in the Bay of Campeche.
The project, worth approximately US$125 million, is scheduled to begin in July 2010 and be completed by the end of December 2010. Global will be utilizing the Hercules as the pipelay vessel and the Titan II as the main operating vessel, with other additional support vessels assisting.
What They Do: Global Industrie is a leading solutions provider of offshore construction, engineering, project management and support services including pipeline construction, platform installation and removal, deepwater/SURF installations, IRM, and diving to the oil and gas industry worldwide.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
